Russia's sovereign wealth fund has agreed on a deal to sell 100 million doses of its Covid-19 vaccine, Sputnik-V, to a major listed pharmaceutical company in India, Reuters reported, quoting a source close to the deal.

Clinical trials of the Russian vaccine in India are expected to follow and to be held jointly with this firm, the source said. Both the trials and supply deal depend on domestic regulatory approval.

RDIF will announce the name of the Indian firm later today, the source said.

Opinion

Editorial

Exit strategy
Updated 18 Mar, 2026

Exit strategy

MOST members of the international community, particularly states in the greater Middle East, are gravely concerned...
Unsafe trains
18 Mar, 2026

Unsafe trains

SUNDAY’S accident involving the Shalimar Express has once again brought into sharp focus the deep structural and...
Disappointment in Dhaka
18 Mar, 2026

Disappointment in Dhaka

FOR a side looking for lift-off after a disappointing T20 World Cup, it was despair for Shaheen Shah Afridi’s ...
Missing in action
17 Mar, 2026

Missing in action

NOT exactly known for playing a proactive role in protecting the interests of Muslim nations and populations...
Risk to stability
Updated 17 Mar, 2026

Risk to stability

THE risks to Pakistan’s fragile economic recovery from the US-Israel war on Iran cannot be dismissed. Yet the...
Enrolment push
17 Mar, 2026

Enrolment push

THE federal government has embarked upon the welcome initiative to enrol 25,000 out-of-school children in Islamabad...